Enzo Biochem (ENZ)
(Delayed Data from NYSE)
$1.05 USD
-0.02 (-1.87%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.06 +0.01 (0.95%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Enzo Biochem, Inc falls in the month of July .
All items in Millions except EPS data.
7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 | 7/31/19 | |
---|---|---|---|---|---|
Sales | 31 | 107 | 118 | 76 | 81 |
Cost Of Goods | 20 | 65 | 64 | 52 | 58 |
Gross Profit | 12 | 42 | 54 | 24 | 23 |
Selling & Adminstrative & Depr. & Amort Expenses | 36 | 57 | 53 | 54 | 22 |
Income After Depreciation & Amortization | -25 | -15 | 1 | -30 | 2 |
Non-Operating Income | 0 | -3 | 7 | 2 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -25 | -18 | 8 | -29 | 2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -25 | -18 | 8 | -29 | 2 |
Extras & Discontinued Operations | 45 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 20 | -18 | 8 | -29 | 2 |
Depreciation Footnote | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 | 7/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -22 | -12 | 3 | -28 | 5 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 3 | 3 | 3 |
Income After Depreciation & Amortization | -25 | -15 | 1 | -30 | 2 |
Earnings Per Share Data | 7/31/23 | 7/31/22 | 7/31/21 | 7/31/20 | 7/31/19 |
---|---|---|---|---|---|
Average Shares | 49.16 | 48.59 | 48.33 | 47.70 | 47.48 |
Diluted EPS Before Non-Recurring Items | -0.51 | -0.23 | 0.21 | -0.51 | -0.56 |
Diluted Net EPS (GAAP) | 0.41 | -0.38 | 0.16 | -0.60 | 0.05 |
Fiscal Year end for Enzo Biochem, Inc falls in the month of July .
All items in Millions except EPS data.
1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 | |
---|---|---|---|---|---|
Sales | 8.55 | 7.81 | -19.66 | 16.11 | 16.34 |
Cost Of Goods | 4.33 | 4.35 | -24.72 | 14.47 | 15.08 |
Gross Profit | 4.22 | 3.46 | 5.06 | 1.64 | 1.26 |
SG&A, R&D, and Dept/Amort Expenses | 6.41 | 8.93 | -8.74 | 17.29 | 14.24 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.19 | -5.47 | 13.80 | -15.65 | -12.98 |
Non-Operating Income | 1.32 | -0.20 | -1.68 | 0.46 | 1.66 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -0.86 | -5.68 | 12.12 | -15.19 | -11.32 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -0.86 | -5.68 | 12.12 | -15.19 | -11.32 |
Extras & Discontinued Operations | -2.20 | -0.94 | 45.31 | 0.00 | 0.00 |
Net Income (GAAP) | -3.06 | -6.62 | 57.43 | -15.19 | -11.32 |
Earnings Per Share Data | 1/31/24 | 10/31/23 | 7/31/23 | 4/30/23 | 1/31/23 |
---|---|---|---|---|---|
Average Shares | 50.49 | 50.18 | NA | 49.38 | 48.73 |
Diluted EPS Before Non-Recurring Items | 0.00 | -0.11 | NA | -0.31 | -0.23 |
Diluted Net EPS (GAAP) | -0.06 | -0.13 | 1.17 | -0.31 | -0.23 |